Tempus AI, Inc. (TEM) News
Follow Tempus AI, Inc. (TEM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 67 public stories across 30 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
TEM Reports FY2026 Q3 Net Profit of -1.351亿美元
Net profit attributable to shareholders was -1.351亿美元, up 29.2% year over year; basic EPS was -0.75美元.
EQUITY | Nov 03, 2026, 04:53 AM UTC
M
Upwork Q3 Revenue Beats Estimates and Acquires WorkMotion
Upwork reported Q3 revenue above analyst estimates and acquired WorkMotion to strengthen its enterprise offering.
EQUITY | Nov 02, 2026, 09:20 PM UTC
M
Tempus AI reports unexpected quarterly profits; shares rise
EARNINGS | Nov 02, 2026, 05:07 PM UTC
M
Tempus AI Rises After Surprise Quarterly Profit
Tempus AI shares rose after the company reported a surprise quarterly profit.
EQUITY | Nov 02, 2026, 05:07 PM UTC
M
Tempus AI shares rise 6.2% after Q3 profit
EQUITY | Nov 02, 2026, 02:40 PM UTC
M
Tempus AI Shares Rise After Record Revenue and Higher 2026 Outlook
Tempus AI reported record third-quarter revenue and raised its 2026 outlook. Shares rose in Monday premarket trading.
EARNINGS | Nov 02, 2026, 01:15 PM UTC
M
Tempus AI Reports Q3 Adjusted EBITDA of $25.572 Million
Q3 adjusted EBITDA was $25.572 million versus the IBES estimate of $18.7 million.
EARNINGS | Nov 02, 2026, 12:33 PM UTC
M
Tempus AI Reports Third-Quarter Revenue of $411.5M
EQUITY | Nov 02, 2026, 12:28 PM UTC
M
Tempus AI Q3 Revenue Slightly Beats Estimates; Raises Guidance
Tempus AI reported Q3 revenue slightly above estimates and raised guidance.
EQUITY | Nov 02, 2026, 12:10 PM UTC
M
Tempus AI Reports Q3 Net Loss
EQUITY | Nov 02, 2026, 12:09 PM UTC
M
Tempus AI cuts Q3 2026 net loss 81%
Tempus AI reported that its net loss fell 81% in the third quarter of 2026.
EQUITY | Nov 02, 2026, 12:09 PM UTC
M
Tempus AI Expects 2026 Revenue of $1.6B to $1.61B
Tempus AI expects 2026 revenue of $1.6 billion to $1.61 billion, versus a FactSet estimate of $1.6 billion.
EARNINGS | Nov 02, 2026, 12:07 PM UTC
M
Tempus AI Q3 Net Loss Narrows 81% to $14.85 Million; Revenue Rises 23% to $411.54 Million
EQUITY | Nov 02, 2026, 12:06 PM UTC
M
Tempus AI Reports Q3 Income From Operations
EARNINGS | Nov 02, 2026, 12:04 PM UTC
M
Tempus AI Reports Q3 Revenue of $411.537 Million
Q3 revenue was $411.537 million, compared with the IBES estimate of $409.4 million.
EQUITY | Nov 02, 2026, 12:03 PM UTC
M
Tempus Reports Third-Quarter 2026 Results
Tempus AI reported its third-quarter 2026 results.
EQUITY | Nov 02, 2026, 12:01 PM UTC
M
Tempus AI Sees FY Revenue at $1.6B-$1.61B
EARNINGS | Nov 02, 2026, 12:01 PM UTC
M
Tempus AI reports third-quarter loss of $14.9 million
EQUITY | Nov 02, 2026, 12:00 PM UTC
M
Tempus AI Q3'26 Earnings Preview
Tempus AI is scheduled to report Q3'26 results on November 2 before the market opens. Revenue and EPS estimates were provided.
EQUITY | Oct 26, 2026, 11:00 AM UTC
M
Tempus AI, Bristol Myers Sign Multi-Year Oncology Data and AI Deals
Tempus AI will license oncological data to Bristol Myers Squibb and provide access to its Lens platform under a multi-year agreement.
EQUITY | Oct 23, 2026, 02:17 PM UTC
M
Pathos AI Signs Multi-Year Deals With BMS and Tempus, Including $55M License
Pathos AI announced collaborations with Bristol Myers Squibb and Tempus AI, including a five-year, $55 million Tempus data license. BMS will lead a Series E financing and receive three-year exclusive rights to apply Path
EQUITY | Oct 23, 2026, 01:01 PM UTC
L
Tempus presents data on AI-enabled NSCLC screening
Tempus presented data demonstrating that AI-enabled pre-screening can help identify patients for biomarker testing in non-small cell lung cancer.
EQUITY | Oct 19, 2026, 12:38 PM UTC
M
Tempus AI to Report Q3 2026 Results Nov. 2
Tempus AI plans to report its Q3 2026 financial results before U.S. markets open on Nov. 2, 2026, and host a webcast at 8:45 a.m. ET.
EQUITY | Oct 15, 2026, 08:01 PM UTC
H
S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today
U.S. stocks extended their advance by midday Tuesday, with the S&P 500 advancing 66 points, or 0.9%, to 7,840, marking a fresh all-time high. The Nasdaq 100 gained 0.8% to 31,317, extending its advance for a sixth straig
LIVE | Oct 06, 2026, 05:11 PM UTC
L
Tempus AI, Inc. (TEM) Gets FDA 510(k) OK for ECG-MR AI
Tempus AI, Inc. received FDA 510(k) clearance for Tempus ECG-MR, software that analyzes 12-lead ECGs to flag signs associated with undiagnosed moderate or severe mitral regurgitation in at-risk patients 65+.Material Deta
REGULATION | Sep 28, 2026, 12:01 PM UTC
L
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (E
REGULATION | Sep 28, 2026, 12:00 PM UTC
M
Tempus extends Recursion data deal to Nov 2029
Tempus AI extended its Recursion data partnership to Nov 2029, amended fees to $42M over three years (replacing potentially $84M over two years), and added a license for Recursion’s RNA sequencing model TxFM.
MNA | Sep 21, 2026, 01:14 PM UTC
M
Tempus AI shares jump amid Medicare revenue optimism
Tempus AI stock rose 15% on Thursday and has advanced 36% over five sessions, after investor focus on expected Medicare reimbursement revenue for two cancer screenings.
EQUITY | Sep 17, 2026, 06:35 PM UTC
L
TEM: AI-driven data and diagnostics, FDA approvals, and strategic deals fuel 25%+ growth outlook
Strong diagnostic and data businesses are driving robust growth, with FDA approvals and pricing upgrades set to deliver significant revenue and margin expansion. Strategic acquisitions and AI-driven data licensing positi
EARNINGS | Sep 15, 2026, 02:22 PM UTC
L
TEM: Robust growth in diagnostics and data, fueled by AI and regulatory wins, drives strong outlook
Strong diagnostic and data licensing growth, driven by robust demand, FDA approvals, and AI adoption, supports a confident outlook for 25%+ annual growth. Strategic acquisitions and partnerships, especially in MRD and va
EARNINGS | Sep 15, 2026, 01:29 PM UTC
L
Cathie Wood Makes Striking Switch Between AI Stock Giants
Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms NASDAQ:META while selling a nearly identical dollar amount of Alphabet NAS
EQUITY | Sep 15, 2026, 12:21 PM UTC
L
Tempus Ai Founder Supports Anthropic CEO’S Call For Slowdown - Bloomberg News
Tempus Ai Founder Supports Anthropic CEO’S Call For Slowdown - Bloomberg News
NEWS | Sep 14, 2026, 08:32 PM UTC
L
Tempus AI CEO Sees Healthcare Sector as Biggest AI Beneficiary — Market Talk
Health tech is most likely to be the biggest beneficiary from AI, Tempus AI Chief Executive Eric Lefkofsky says on CNBC. AI models can make sense of large amounts of unstructured disparate data, which is the form most he
NEWS | Sep 14, 2026, 07:58 PM UTC
M
Goldman rebalances its long duration stock basket
The Goldman Sachs equity team has rebalanced its Long Duration Basket amid rising interest rates.Equities usually struggle to digest sharp increases in interest rates, with long duration growth stocks struggling dispropo
EQUITY | Sep 13, 2026, 02:13 PM UTC
M
Tempus to receive up to $9.5 million in ARPA-H ADVOCATE funding
Tempus AI, Inc. said it has been selected by ARPA-H to receive an award of up to $9.5 million to build the first autonomous clinical AI agent for cardiology.
EQUITY | Sep 09, 2026, 08:01 PM UTC
L
UBS initiates Tempus AI at neutral
UBS initiated coverage on Tempus AI with a neutral rating.
EQUITY | Sep 09, 2026, 01:35 PM UTC
L
Rothschild & Co initiates Tempus AI at neutral, $67 target
Rothschild & Co initiated coverage of Tempus AI at a neutral rating and set a $67.00 per-share price target, according to TradingView News via Benzinga ratings actions.
EQUITY | Sep 08, 2026, 03:50 PM UTC
L
Roth Capital sets Tempus AI price target at $67.00
Roth Capital announced a $67.00/share price target for Tempus AI and initiated coverage at Neutral.
EQUITY | Sep 08, 2026, 12:34 PM UTC
L
TEM - Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
TEM - Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Sep 04, 2026, 12:32 PM UTC
L
Tempus CEO Lefkofsky to join fireside chat at Morgan Stanley conference
Tempus AI, Inc. says Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 8:30 a.m. ET in New York City.
EQUITY | Sep 04, 2026, 12:30 PM UTC
L
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels - Heard on the Street — WSJ
By David WainerThe excitement surrounding Moderna and Merck's personalized mRNA cancer vaccine added more than $50 billion in combined market value for the two drug companies. But it is also creating a gold rush in a gro
COMMODITIES | Sep 04, 2026, 09:30 AM UTC
L
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
AUSTIN, Texas, Sept. 3, 2026 // -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug dis
EQUITY | Sep 03, 2026, 12:55 PM UTC
L
Cantor Fitzgerald starts Tempus AI at Overweight
Cantor Fitzgerald initiated a ratings action with Tempus AI rated Overweight.
EQUITY | Sep 02, 2026, 11:19 AM UTC
L
Ark Invest sells Tempus AI and trims AMD holdings
Cathie Wood-led Ark Invest sold 250,062 Tempus AI shares through ARKK and trimmed AMD via ARKQ and ARKX on Tuesday.
EQUITY | Sep 02, 2026, 02:34 AM UTC
L
Tempus AI upgraded to Overweight from Neutral by Piper Sandler
Piper Sandler raised its rating on Tempus AI to Overweight from Neutral and lifted its price target to $76.00 per share from $56.00, per TradingView News via Benzinga.
EQUITY | Sep 01, 2026, 04:58 PM UTC
M
Piper Sandler upgrades Tempus AI to Overweight, lifts target to $76
Tempus AI gained 2.46% premarket after Piper Sandler upgraded it to Overweight from Neutral and raised its price target to $76 from $56.
EQUITY | Sep 01, 2026, 01:46 PM UTC
L
Cathie Wood Drops $124 Million on AI Stocks, Dumps AMD
Cathie Wood Drops $124 Million on AI Stocks, Dumps AMD
EQUITY | Sep 01, 2026, 01:46 AM UTC
L
REG - TempletonEmerg.Mkt. - Holding(s) in Company
REG - TempletonEmerg.Mkt. - Holding(s) in Company
EQUITY | Aug 26, 2026, 02:43 PM UTC
L
Tempus AI gains as BTIG lifts price target, cancer trial readthrough in focus
Tempus AI Inc. shares are trading higher Thursday after BTIG maintained a Buy rating and raised its price forecast to $80, while investors also focus on a Phase 3 cancer trial readthrough tied to the pending Personalis a
EQUITY | Aug 20, 2026, 12:35 PM UTC
L
TEM price target raised to $80 at BTIG
BTIG raised its price target for TEM to $80, according to TradeXchange Newsdesk.
EQUITY | Aug 20, 2026, 11:14 AM UTC
M
Tempus AI jumps after Merck-Moderna melanoma trial results
Tempus AI shares are rising after Merck and Moderna released Phase 3 INTerpath-001 results for intismeran autogene in resected melanoma, which traders linked to Tempus’s planned Personalis acquisition.
EQUITY | Aug 19, 2026, 02:57 PM UTC
L
Tempus rises premarket on Merck, Moderna collaboration news
Tempus shares are up 13% premarket after market talk pointed to expanded strategic collaboration with Merck and an ongoing expanded partnership with Moderna through Tempus AI data platforms.
MNA | Aug 19, 2026, 01:03 PM UTC
L
Why Is Tempus AI Stock Surging on Friday?
Tempus AI Inc. (NASDAQ: TEM ) stock is surging over 11% on Friday at the time of publication. The price movement is primarily driven by a broader AI-healthcare technology sector rally sparked by stellar earnings and guid
EARNINGS | Aug 07, 2026, 06:21 PM UTC
L
Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset?
Tempus AI Inc. (NASDAQ: TEM ) shares are trading lower on Friday as traders digest post-earnings reset in expectations. Tempus AI stock is trending lower. Why is TEM stock trading lower? What To Watch After Tempus AI’s Q
EARNINGS | Jul 31, 2026, 02:51 PM UTC
L
Why Nancy Pelosi-Owned Tempus AI Stock Is Down After Q2 Earnings
Tempus AI (NASDAQ: TEM ) reported second-quarter financial results Thursday after market close. Here are the key highlights. • Tempus AI stock is facing resistance. Why are TEM shares declining? Tempus AI Q2 Earnings Tem
EARNINGS | Jul 30, 2026, 09:06 PM UTC
L
TEM Q2 adj EPS loss (-$0.04) vs. est. loss (-$0.14); Q2 revs $382.5M vs. est. $379.7M; Q2 operating loss -$75.9M; guides FY revs $1.595B-$1.
TEM Q2 adj EPS loss (-$0.04) vs. est. loss (-$0.14); Q2 revs $382.5M vs. est. $379.7M; Q2 operating loss -$75.9M; guides FY revs $1.595B-$1.605B vs. est. $1.59B and backs FY26 adjusted EBITDA view roughly $65M after Q2 a
EARNINGS | Jul 30, 2026, 08:08 PM UTC
L
TEM - Tempus Reports Second Quarter 2026 Results
TEM - Tempus Reports Second Quarter 2026 Results
EARNINGS | Jul 30, 2026, 08:05 PM UTC
L
Tempus AI Raises FY2026 Sales Guidance from $1.590B-$1.600B to $1.595B-$1.605B vs $1.593B Est
Tempus AI (NASDAQ: TEM ) raises FY2026 sales outlook from $1.590 billion-$1.600 billion to $1.595 billion-$1.605 billion vs $1.593 billion estimate.
EARNINGS | Jul 30, 2026, 08:03 PM UTC
H
Bulls and Bears: IBM, Super Micro, Tesla
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks endured a difficult week as a renewed surge in oil prices and disappointing reactions
MACRO | Jul 25, 2026, 12:00 PM UTC
L
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
On Monday, Tempus AI, Inc. (NASDAQ: TEM ) agreed to acquire Personalis, Inc. (NASDAQ: PSNL ), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities. Tempus AI shares erased earl
RATES | Jul 21, 2026, 06:52 PM UTC